Legal & General Group Plc Trims Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Legal & General Group Plc decreased its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 10.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,431,197 shares of the life sciences company's stock after selling 160,563 shares during the period. Legal & General Group Plc owned 0.90% of Illumina worth $191,251,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Versant Capital Management Inc grew its stake in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new position in shares of Illumina in the fourth quarter worth $32,000. Assetmark Inc. grew its position in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina during the 4th quarter valued at $45,000. Finally, Lee Danner & Bass Inc. purchased a new stake in Illumina during the 4th quarter worth about $48,000. Institutional investors own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ILMN shares. Barclays decreased their price target on Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research report on Thursday, April 10th. Piper Sandler increased their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Stephens restated an "overweight" rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective on the stock. in a research report on Friday, February 28th. Finally, Morgan Stanley reduced their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $138.70.

Remove Ads

Illumina Trading Down 0.4 %

Shares of Illumina stock traded down $0.33 during trading on Tuesday, reaching $74.73. 291,652 shares of the stock were exchanged, compared to its average volume of 2,262,910. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market cap of $11.84 billion, a price-to-earnings ratio of -9.73, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The stock's fifty day moving average is $87.59 and its 200 day moving average is $121.87.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.